The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with breast cancer or at high risk of developing it.
I. Sestak
No relevant relationships to disclose
M. Harvie
No relevant relationships to disclose
A. Howell
Honoraria - Amgen; AstraZeneca; GlaxoSmithKline
Expert Testimony - AstraZeneca
J. F. Forbes
Honoraria - AstraZeneca
M. Dowsett
Consultant or Advisory Role - AstraZeneca
Honoraria - AstraZeneca
Research Funding - AstraZeneca
Expert Testimony - AstraZeneca
J. M. Cuzick
Consultant or Advisory Role - AstraZeneca
Research Funding - AstraZeneca